Aydilek Dagdeviren Cakir

Aydilek Dagdeviren Cakir

Auto-generated profile, based on publicly available information

Aydilek Dagdeviren Cakir

University of Health Sciences, Şişli Hamidiye Etfal Health Practices and Research Centre, Division of Pediatric Endocrinology, Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2016 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
ADAydilek Dağdeviren-Çakır
Aydilek Dağdeviren-Çakır
AAAhmet Arvas
Ahmet Arvas
KBKenan Barut
Kenan Barut
EGEmel Gür
Emel Gür
OKOzgur Kasapcopur
Ozgur Kasapcopur
The aim of this study was to determine the frequency of vitamin D deficiency and/or insufficiency in children with juvenile idiopathic arthritis (JIA) and familial Mediterranean fever (FMF) and to assess the relationship between vitamin D and disease activity. Sixty four patients with JIA, thirty six patients with FMF and one hundred healthy children were enrolled in this study. Vitamin D levels were measured during activation and remission periods in the patients with JIA and during attack and attack free periods in the patients with FMF. The mean vitamin D levels were found to be 18. 9±11 ng/ml and 18.6±9.2 ng/ml during activation and remission periods of disease, respectively, in the patients with JIA, 16±8.5 ng/ml and 13.1±6.4 ng/ml during attack and attack-free periods, respectively, in the patients with FMF and 26.7±10.5 ng/ml in the healthy children. There was no significant difference between vitamin D levels during activation and remission periods in the patients with JIA, whereas vitamin D levels during attack free periods were lower compared to attack periods in the patients with FMF. No significant relationship was found between disease activity and serum vitamin D levels. The vitamin D levels of the children with JIA and FMF were significantly lower compared to the healthy children. The frequency of vitamin D deficiency and insufficiency was considerably high among the patients with JIA and FMF.

18 May 2018 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
OEOlcay Evliyaoglu
Olcay Evliyaoglu
OEOya Ercan
Oya Ercan
EAEmel Ataloğlu
Emel Ataloğlu
ÜZÜmit Zübarioğlu
Ümit Zübarioğlu
BÖBahar Özcabı
Bahar Özcabı
SESian Ellard
Sian Ellard
Neonatal diabetes mellitus is a rare form of monogenic diabetes which is diagnosed in the first six months of life. Here we report three patients with neonatal diabetes; two with isolated pancreas agenesis due to mutations in the pancreas-specific transcription factor 1A (PTF1A) enhancer and one with developmental delay, epilepsy, and neonatal diabetes (DEND) syndrome, due to a KCNJ11 mutation. The two cases with mutations in the distal enhancer of PTF1A had a homozygous g.23508363A > G and a homozygous g.23508437A > G mutation respectively. Previous functional analyses showed that these mutations can decrease expression of PTF1A which is involved in pancreas development. Both patients were born small for gestational age to consanguineous parents. Both were treated with insulin and pancreatic enzymes. One of these patients' fathers was also homozygous for the PTF1A mutation, whilst his partner and the parents of the other patient were heterozygous carriers. In the case with DEND sydrome, a previosly reported heterozygous KCNJ11 mutation, p.Cys 166Tyr (c.497G > A), was identified. This patient was born to nonconsanguineous parents with normal birth weight. The majority of neonatal diabetes patients with KCNJ11 mutations will respond to sulphonylurea treatment. Therefore Glibenclamide, an oral antidiabetic of the sulphonylurea group, was started. This treatment regimen relatively improved blood glucose levels and neurological symptoms in the short term. Because we could not follow the patient in the long term, we are not able to draw conclusions about the efficacy of the treatment. Although neonatal diabetes mellitus can be diagnosed clinically, genetic analysis is important since it is a guide for the treatment and for prognosis.

24 March 2020 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
SSSeha Kamil Saygili
Seha Kamil Saygili
NCNur Canpolat
Nur Canpolat
ACAydilek Cakir
Aydilek Cakir
DKDildar Konukoglu
Dildar Konukoglu
HTHande Turan
Hande Turan
LSLale Sever
Lale Sever

23 May 2018 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
SPSukran Poyrazoglu
Sukran Poyrazoglu
RBRüveyde Bundak
Rüveyde Bundak
ZAZehra Yavaş Abal
Zehra Yavaş Abal
HÖHasan Önal
Hasan Önal
SSSevil Sarıkaya
Sevil Sarıkaya
FDFeyza F. Darendeliler
Feyza F. Darendeliler
Objective: To assess the incidence of type I diabetes mellitus (T1DM) in children under 18 years of age in the northwest region of Turkey during 2013-2015. Methods: All newly diagnosed T1DM cases were recorded prospectively during 2013-2015. Total, as well as gender and age group specific (0-4, 5-9. 10-14 and 15-17 age) mean incidences per 100,000 per year were calculated. Results: There were 1,773 patients diagnosed during 2013-2015 (588 cases in 2013, 592 cases in 2014, 593 cases in 2015). Of these, 862 (48.6 %) were girls and 911 (51.4%)were boys. The mean age at diagnosis was 9.2 +/- 4.2 years and it was not significantly different between girls (9.0 +/- 4.1 years) and boys (9.4 +/- 4.4 years) (p = 0.052). The crude mean incidence was 8.99/100.000 confidence interval (CI) (95% CI: 8.58-9.42). Although mean incidence was similar between boys [8.98/100.000 (CI: 8.40 to 9.58)] and girls [9.01/100.000 (CI: 8.42 to 9.63)], there was male predominance in all groups except for 5-9 year age group. The standardized mean incidence was 9.02/100.000 according to the World Health Organization standard population. The mean incidence for the 0-4, 5-9, 10-14 and 15-17 age groups was 6.13, 11.68, 11.7 and 5.04/1 00.000 respectively. The incidence of T1DM was similar over the course of three years (p = 0.95). A significant increase in the proportion of cases diagnosed was observed in the autumn-winter seasons. Conclusion: The northwest region of Turkey experienced an intermediate incidence of T1DM over the period of the study.

23 August 2021 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
PDF file
AÇAydilek Dağdeviren Çakır
Aydilek Dağdeviren Çakır
FBFirdevs Baş
Firdevs Baş
OAOnur Akın
Onur Akın
ZSZeynep Siklar
Zeynep Siklar
BÖBahar Özcabı
Bahar Özcabı
OEOlcay Evliyaoglu
Olcay Evliyaoglu
To investigate clinical characteristics and response to growth hormone (GH) treatment in patients with Prader-Willi syndrome (PWS) in Turkey. The data of 52 PWS patients from ten centers was retrospectively analyzed. A nation-wide, web-based data system was used for data collection. Demographic, clinical, genetic, and laboratory data and follow-up information of the patients were evaluated. The median age of patients at presentation was 1.5 years, and 50% were females. Genetic analysis showed microdeletion in 69.2%, uniparental disomy in 11.5%, imprinting defect in 1.9% and methylation abnormality in 17.3%. Hypotonia (55.7%), feeding difficulties (36.5%) and obesity (30.7%) were the most common complaints. Cryptorchidism and micropenis were present in 69.2% and 15.3% of males, respectively. At presentation, 25% had short stature, 44.2% were obese, 9.6% were overweight and 17.3% were underweight. Median age of obese patients was significantly higher than underweight patients. Central hypothyroidism and adrenal insufficiency were present in 30.7% and 4.7%, respectively. Hypogonadism was present in 75% at normal age of puberty. Growth hormone treatment was started in 40% at a mean age of 4.7±2.7 years. After two years of GH treatment, a significant increase in height SDS was observed. However, BMI SDS remained unchanged. The most frequent complaints were hypotonia and feeding difficulty at first presentation. Obesity was the initial finding in 44.2%. Growth hormone treatment was started in less than half of the patients. While GH treatment significantly increased height SDS, BMI SDS remained unchanged, possibly due to the relatively older age at GH start.

18 May 2018 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
AÇAydilek Dağdeviren Çakır
Aydilek Dağdeviren Çakır
HTHande Turan
Hande Turan
AAAyca Aykut
Ayca Aykut
ADAsude Durmaz
Asude Durmaz
OEOya Ercan
Oya Ercan
OEOlcay Evliyaoglu
Olcay Evliyaoglu
Von Hippel-Lindau (VHL) disease is an autosomal dominantly inherited disorder, characterized by hemangioblastomas of the retina and central nervous system (CNS); renal cysts; clear cell carcinoma; pheochromocytoma (PCC); endolymphatic sac tumors; cystadenomas of the epididymis in males; broad ligament of uterus in females; pancreatic cysts; cystadenomas; and neuroendocrine tumors. We report two cases of VHL disease that presented with PCC as the first manifestation. Further clinical developments during follow-up, hemangioblastoma of CNS in one case and a pancreatic neuroendocrine tumor (PNET) in the second case led to the diagnosis of VHL disease. Genetic analyses of the two cases revealed p.Arg161Gln (c.482G>A) and p.Leu129Pro (c.386T>G) heterozygous missense mutations in the VHL gene, respectively. In children, PCC may be the only and/or initial manifestation of VHL with delayed manifestations of the syndrome in other organs. PNET is a very rare manifestation of VHL disease. To the best of our knowledge, this is only the second reported case presenting with a combination of a PNET and bilateral PCC as components of childhood VHL disease. Pediatric patients diagnosed with PCC should be investigated for genetic causes and especially for VHL.